(S (NP (NP (DT The) (JJ increased) (NN affordability)) (PP (IN of) (NP (JJ whole) (NN genome) (NN sequencing)))) (VP (VBZ has) (VP (VBN motivated) (NP (NP (PRP$ its) (NN use)) (PP (IN for) (NP (NN phenotypic) (NNS studies)))))) (. .))
(S (NP (PRP We)) (VP (VBP address) (NP (NP (DT the) (NN problem)) (PP (IN of) (S (VP (VBG learning) (NP (NP (JJ interpretable) (NNS models)) (PP (IN for) (NP (JJ discrete) (NNS phenotypes)))) (PP (IN from) (NP (JJ whole) (NNS genomes)))))))) (. .))
(S (NP (PRP We)) (VP (VBP propose) (NP (NP (DT a) (JJ general) (NN approach)) (SBAR (WHNP (WDT that)) (S (VP (VBZ relies) (PP (IN on) (NP (NP (DT the) (NNP Set) (NNP Covering) (NNP Machine)) (CC and) (NP (NP (DT a) (JJ k-mer) (NN representation)) (PP (IN of) (NP (DT the) (NNS genomes))))))))))) (. .))
(S (NP (PRP We)) (VP (VBP show) (NP (NP (NNS results)) (PP (IN for) (NP (NP (DT the) (NN problem)) (PP (IN of) (S (VP (VBG predicting) (NP (NP (DT the) (NN resistance)) (PP (IN of) (NP (NP (NNP Pseudomonas) (NNP Aeruginosa)) (, ,) (NP (DT an) (JJ important) (JJ human) (NN pathogen)) (, ,))) (PP (IN against) (NP (CD 4) (NNS antibiotics))))))))))) (. .))
(S (NP (PRP$ Our) (NNS results)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (ADJP (RB extremely) (JJ sparse)) (NNS models)) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (ADJP (RB biologically) (JJ relevant)))))) (VP (MD can) (VP (VB be) (VP (JJ learnt) (S (VP (VBG using) (NP (DT this) (NN approach)))))))))) (. .))
